Endo International PLC (ENDP) Receives Consensus Recommendation of “Hold” from Analysts
Endo International PLC (NASDAQ:ENDP) (TSE:ENL) has received a consensus recommendation of “Hold” from the twenty-four analysts that are currently covering the firm, Marketbeat Ratings reports. Three investment analysts have rated the stock with a sell rating, sixteen have given a hold rating and five have issued a buy rating on the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $12.37.
Several equities analysts have recently commented on the stock. Canaccord Genuity set a $10.00 target price on shares of Endo International PLC and gave the stock a “hold” rating in a report on Monday, August 14th. Deutsche Bank AG decreased their price target on shares of Endo International PLC from $18.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday, July 7th. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $9.00 price target (down previously from $15.00) on shares of Endo International PLC in a research note on Wednesday, August 9th. Cowen and Company reaffirmed a “hold” rating and set a $16.00 price target on shares of Endo International PLC in a research note on Thursday, August 10th. Finally, Citigroup Inc. reaffirmed a “neutral” rating and set a $11.00 price target (down previously from $14.00) on shares of Endo International PLC in a research note on Thursday, August 10th.
Endo International PLC (ENDP) traded down 2.03% during mid-day trading on Friday, hitting $7.72. 3,101,745 shares of the stock traded hands. The company’s market cap is $1.72 billion. The company’s 50 day moving average is $8.52 and its 200 day moving average is $10.43. Endo International PLC has a 12 month low of $7.40 and a 12 month high of $21.87.
Endo International PLC (NASDAQ:ENDP) (TSE:ENL) last released its earnings results on Tuesday, August 8th. The company reported $0.93 EPS for the quarter, topping the consensus estimate of $0.74 by $0.19. Endo International PLC had a negative net margin of 126.93% and a positive return on equity of 37.58%. The firm had revenue of $875.73 million for the quarter, compared to the consensus estimate of $832.66 million. During the same quarter in the previous year, the firm earned $0.86 earnings per share. The company’s quarterly revenue was down 4.9% compared to the same quarter last year. On average, analysts expect that Endo International PLC will post $3.52 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This news story was originally posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international trademark and copyright law. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/22/endo-international-plc-endp-receives-consensus-recommendation-of-hold-from-analysts.html.
In other Endo International PLC news, COO Terrance J. Coughlin bought 20,000 shares of the company’s stock in a transaction on Thursday, August 10th. The shares were bought at an average cost of $7.70 per share, for a total transaction of $154,000.00. Following the acquisition, the chief operating officer now directly owns 181,369 shares in the company, valued at $1,396,541.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Paul Campanelli bought 6,500 shares of the company’s stock in a transaction on Monday, August 14th. The shares were acquired at an average price of $7.71 per share, for a total transaction of $50,115.00. Following the completion of the acquisition, the chief executive officer now owns 213,620 shares in the company, valued at $1,647,010.20. The disclosure for this purchase can be found here. Over the last quarter, insiders have acquired 36,000 shares of company stock worth $279,460. 0.50% of the stock is owned by company insiders.
Large investors have recently added to or reduced their stakes in the company. James Investment Research Inc. bought a new stake in shares of Endo International PLC in the 2nd quarter valued at about $113,000. Blair William & Co. IL bought a new stake in shares of Endo International PLC in the 2nd quarter valued at about $126,000. Point View Wealth Management Inc. boosted its holdings in shares of Endo International PLC by 16.6% in the 2nd quarter. Point View Wealth Management Inc. now owns 13,331 shares of the company’s stock valued at $149,000 after buying an additional 1,900 shares in the last quarter. Riverhead Capital Management LLC boosted its holdings in shares of Endo International PLC by 64.4% in the 2nd quarter. Riverhead Capital Management LLC now owns 15,025 shares of the company’s stock valued at $168,000 after buying an additional 5,887 shares in the last quarter. Finally, Bank of Hawaii bought a new stake in shares of Endo International PLC in the 2nd quarter valued at about $180,000. Institutional investors and hedge funds own 90.71% of the company’s stock.
About Endo International PLC
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.